Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 2,237 shares of Bicycle Therapeutics stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $8.02, for a total transaction of $17,940.74. Following the completion of the transaction, the chief executive officer now owns 489,697 shares in the company, valued at approximately $3,927,369.94. This trade represents a 0.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Bicycle Therapeutics Price Performance
Shares of NASDAQ BCYC traded up $0.17 during trading hours on Wednesday, hitting $6.55. 236,540 shares of the company's stock were exchanged, compared to its average volume of 392,051. Bicycle Therapeutics plc has a 1-year low of $6.13 and a 1-year high of $28.67. The company's 50-day moving average price is $10.38 and its 200-day moving average price is $16.49. The stock has a market capitalization of $452.93 million, a price-to-earnings ratio of -1.94 and a beta of 1.40.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company's quarterly revenue was down 30.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.16) EPS. On average, research analysts expect that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on BCYC. Stephens reissued an "equal weight" rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Needham & Company LLC restated a "buy" rating and set a $30.00 price target on shares of Bicycle Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. JMP Securities cut their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a research note on Wednesday, December 18th. Finally, B. Riley decreased their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $29.14.
Check Out Our Latest Analysis on BCYC
Institutional Investors Weigh In On Bicycle Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC raised its position in Bicycle Therapeutics by 878.3% in the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after purchasing an additional 2,345 shares in the last quarter. Avior Wealth Management LLC bought a new stake in Bicycle Therapeutics in the fourth quarter valued at $57,000. JPMorgan Chase & Co. lifted its holdings in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after acquiring an additional 1,782 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Bicycle Therapeutics by 879.5% during the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock valued at $76,000 after acquiring an additional 8,065 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after purchasing an additional 2,191 shares during the last quarter. Institutional investors own 86.15% of the company's stock.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Featured Articles
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
